Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A90249%2F23%3A00135351" target="_blank" >RIV/00216224:90249/23:00135351 - isvavai.cz</a>

Výsledek na webu

<a href="https://test.uhkt.cz/clinical-trials/clinical-trials" target="_blank" >https://test.uhkt.cz/clinical-trials/clinical-trials</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023)

Popis výsledku v původním jazyce

Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023) Report No. 3 was prepared on the progress of the clinical evaluation 9/6/2022 - 8/6/2023: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-Iabel, phase I study: EudraCT project 2018-004789-32, code UHKT-CAR19-01.

Název v anglickém jazyce

Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023)

Popis výsledku anglicky

Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023) Report No. 3 was prepared on the progress of the clinical evaluation 9/6/2022 - 8/6/2023: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-Iabel, phase I study: EudraCT project 2018-004789-32, code UHKT-CAR19-01.

Druh

V_souhrn - Souhrnná výzkumná zpráva

CEP obor

—

OECD FORD obor

30230 - Other clinical medicine subjects

Projekt

—

Návaznosti

—

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Počet stran výsledku

4

Místo vydání

Praha

Název nakladatele resp. objednatele

ÚHKT PRAHA

Verze

—